Creat de Shyam Sunder

AJANTPHARM

AJANTPHARM corporate announcements

Ajanta Pharma Gets Approvals For 3 ANDA's (Company Update)
Autor
Investor Presentation (Company Update)
Autor
Fortune India Presents Award To Ajanta Pharma (Company Update)
Autor
Ajanta Pharma Announces The Launch of Montelukast Sodium Oral Granules (Company Update)
Autor
Ajanta Pharma Receives US FDA Approval For Almotriptan Malate Tablets (Company Update)
Autor
Authorised KMPs To Determine Materiality of Events/information (Company Update)
Autor
Ajanta Pharma Announces The Launch of Montelukast IR Tablets and Montelukast Chewable Tablets (Company Update)
Autor
Ajanta Pharma Announces The Launch of Levetiracetam Tablets (Company Update)
Autor
Ajanta Pharma Announces US FDA Approval of Voriconazole Tablets (Company Update)
Autor
Ajanta Pharma Announces The US FDA Approval of Zolmitriptan Tablets (Company Update)
Autor
Investor Presentation Q4 FY 2016 (Company Update)
Autor
Presentation On Results (Company Update)
Autor
Announces Q1 (Standalone & Consolidated) Results, Limited Review Report (Standalone & Consolidated) & Results Press Release For The Quarter Ended June 30, 2016 (Result)
Autor
Investor Presentation Q1 FY 2017 (Company Update)
Autor
Q2 Results On Oct 26, 2016 (Board Meeting)
Autor
Investor Presentation (Company Update)
Autor
Ajanta Pharma Announces US FDA Approval For Omeprazole and Sodium Bicarbonate Powder For Oral Suspension (Company Update)
Autor
Ajanta Pharma Announces Consolidation of Promoter Shareholding (Company Update)
Autor
Ajanta Pharma Announces Approval of Aripiprazole Tablets From US FDA (Company Update)
Autor
Ajanta Pharma Announces Approval & Launch of Amlodipine + Olmesartan Medoxomil Tablets in US Market (Company Update)
Autor
No Import Alert On Us by US FDA (Company Update)
Autor
Ajanta Pharma Announces US FDA Approval For Duloxetine Hydrochloride Delayed Release Capsules (Company Update)
Autor
Investor Presentation Q3 FY 2017 (Company Update)
Autor
Clarifies On News Item (Company Update)
Autor

AJANTPHARM

Ajanta Pharma Gets Approvals For 3 ANDA's (Company Update)

Investor Presentation (Company Update)

Fortune India Presents Award To Ajanta Pharma (Company Update)

Ajanta Pharma Announces The Launch of Montelukast Sodium Oral Granules (Company Update)

Ajanta Pharma Receives US FDA Approval For Almotriptan Malate Tablets (Company Update)

Authorised KMPs To Determine Materiality of Events/information (Company Update)

Ajanta Pharma Announces The Launch of Montelukast IR Tablets and Montelukast Chewable Tablets (Company Update)

Ajanta Pharma Announces The Launch of Levetiracetam Tablets (Company Update)

Ajanta Pharma Announces US FDA Approval of Voriconazole Tablets (Company Update)

Ajanta Pharma Announces The US FDA Approval of Zolmitriptan Tablets (Company Update)

Investor Presentation Q4 FY 2016 (Company Update)

Presentation On Results (Company Update)

Announces Q1 (Standalone & Consolidated) Results, Limited Review Report (Standalone & Consolidated) & Results Press Release For The Quarter Ended June 30, 2016 (Result)

Investor Presentation Q1 FY 2017 (Company Update)

Q2 Results On Oct 26, 2016 (Board Meeting)

Investor Presentation (Company Update)

Ajanta Pharma Announces US FDA Approval For Omeprazole and Sodium Bicarbonate Powder For Oral Suspension (Company Update)

Ajanta Pharma Announces Consolidation of Promoter Shareholding (Company Update)

Ajanta Pharma Announces Approval of Aripiprazole Tablets From US FDA (Company Update)

Ajanta Pharma Announces Approval & Launch of Amlodipine + Olmesartan Medoxomil Tablets in US Market (Company Update)

No Import Alert On Us by US FDA (Company Update)

Ajanta Pharma Announces US FDA Approval For Duloxetine Hydrochloride Delayed Release Capsules (Company Update)

Investor Presentation Q3 FY 2017 (Company Update)

Clarifies On News Item (Company Update)